LD-2 disclosure · 4th Quarter - Report
THE BIOSIMILARS FORUM
Client
- Description
- Non-profit Organization
- Location
- District of Columbia · United States of America
Registrant
- Description
- Government Affairs Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
LobbyistsALEX DELPIZZO · STUART CHAPMAN · mrs THAYER SURETTE ROBERTS
Covered position (ALEX DELPIZZO): Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee
Covered position (STUART CHAPMAN): Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)
Health Issues
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.